¼¼°èÀÇ ºÎµ¥¼Ò´Ïµå ÈíÀԱ⠽ÃÀå º¸°í¼­(2025³â)
Budesonide Inhaler Global Market Report 2025
»óǰÄÚµå : 1760495
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,235,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,013,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,790,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºÎµ¥¼Ò´Ïµå ÈíÀԱ⠽ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 8.7%ÀÇ CAGR·Î 96¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº È£Èí±â Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, È£Èí±â Ä¡·á¿¡¼­ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¿ø°ÝÀÇ·á ¹× ÀüÀÚ Ã³¹æÀÇ »ç¿ë È®´ë, Á¶±â Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÈíÀԱ⠺´¿ë¿ä¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¾à¹°Àü´ÞÀ» °³¼±Çϱâ À§ÇÑ Ã·´Ü Á¦Çü ±â¼ú, µðÁöÅÐ ÃßÀû ±â´ÉÀ» °®Ãá ½º¸¶Æ® ÈíÀÔ±âÀÇ Çõ½Å, È£Èí±â °Ç°­ °ü¸®¿¡ AI¿Í IoTÀÇ ÅëÇÕ, ȯÀÚ Á᫐ ¾à¹° ¼³°èÀÇ ¹ßÀü, ¼øÀÀµµ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¸ð¹ÙÀÏ ¾ÛÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù.

È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È ºÎµ¥¼Ò´Ïµå ÈíÀԱ⠽ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æó¿Í È£Èí±â¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â È£Èí±âÁúȯÀº È£ÈíÀ» ¾î·Æ°Ô Çϰí Á¾Á¾ ±âħ, õ¸íÀ½, È£Èí°ï¶õ µîÀÇ Áõ»óÀ» À¯¹ßÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áúȯ¿¡´Â õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó·Å, ±â°üÁö¿°, Æó °¨¿° µîÀÌ Æ÷ÇԵ˴ϴÙ. È£Èí±âÁúȯÀÇ Áõ°¡´Â ´ë±â¿À¿°ÀÇ Áõ°¡·Î ÀÎÇØ ±âµµ¸¦ ÀÚ±ØÇÏ°í Æó ±â´ÉÀ» ¾ÇÈ­½ÃŰ´Â À¯ÇØÇÑ ¿À¿°¹°Áú¿¡ ³ëÃâµÇ´Â ´ë±â¿À¿°ÀÇ Áõ°¡¿¡ Å©°Ô ±âÀÎÇÕ´Ï´Ù. ºÎµ¥¼Ò´Ïµå ÈíÀÔÁ¦´Â Ç׿°ÁõÁ¦¸¦ Æó¿¡ Á÷Á¢ Åõ¿©ÇÏ¿© ÀÌ·¯ÇÑ ÁúȯÀ» Àå±âÀûÀ¸·Î °ü¸®ÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÄÄÆÑÆ®ÇÑ µðÀÚÀÎÀ¸·Î »ç¿ë ÆíÀǼº°ú È޴뼺À» º¸ÀåÇϰí Àç¹ßÀ» ¹æÁöÇϸç È£Èí±â °Ç°­À» °³¼±ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, È£ÁÖ Åë°èû¿¡ µû¸£¸é È£ÁÖÀÇ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) À¯º´·üÀº 2021³â 2.4%¿¡¼­ 2022³â 2.5%·Î Áõ°¡Çß½À´Ï´Ù. °á°úÀûÀ¸·Î È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡´Â ºÎµ¥¼Ò´Ïµå ÈíÀԱ⠽ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎµ¥¼Ò´Ïµå ÈíÀԱ⠽ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº Àú·ÅÇÑ °¡°ÝÀ¸·Î È£Èí±âÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖµµ·Ï Á¦³×¸¯ ÀǾàǰ°ú °°Àº Çõ½ÅÀûÀÎ Á¦Ç° °³¹ß¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÈíÀÔÁ¦´Â ºê·£µå Á¦Ç°°ú µ¿ÀÏÇÑ È°¼º ¼ººÐ, ¿ë·® ¹× Ä¡·á È¿°ú¸¦ Æ÷ÇÔÇÏ´Â ºñºê·£µå Á¦Ç°ÀÇ ´ëüǰÀÌÁö¸¸ °¡°ÝÀº ´õ Àú·ÅÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù Viatris Inc.´Â Kindeva Drug Delivery L.P.¿Í Á¦ÈÞÇÏ¿© FDA°¡ ½ÂÀÎÇÑ ÃÖÃÊÀÇ ½ÉºñÄÚÆ® Á¦³×¸¯ ÀǾàǰÀÎ Breyna(ºÎµ¥¼Ò´Ïµå Ǫ¸¶¸£»ê Æ÷¸£¸ðÅ×·Ñ À̼öÈ­ÇÕ¹°) ÈíÀÔ¿ë ¿¡¾î·ÎÁ¹À» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ¾à¹°°ú ±â±âÀÇ Á¶ÇÕÀº ºÎµ¥¼Ò´Ïµå·Î ±âµµÀÇ ¿°ÁõÀ» ¾ïÁ¦Çϰí, È£¸£¸óÀÎ Æ÷¸£¸ðÅ×·Ñ·Î ±âµµ ÁÖº¯ ±ÙÀ°À» À̿ϽÃÄÑ Ãµ½Ä°ú COPD¸¦ Ä¡·áÇϵµ·Ï ¼³°èµÇ¾î ȯÀڵ鿡°Ô º¸´Ù ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The budesonide inhaler is a respiratory device that delivers the corticosteroid medication budesonide directly to the lungs. It helps reduce airway inflammation, making breathing easier. The budesonide inhaler is typically prescribed for the long-term management of respiratory diseases.

The main types of products in the budesonide inhaler market include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and combination inhalers. Metered-dose inhalers (MDIs) are handheld medical devices that deliver a precise amount of medication directly to the lungs in the form of a short burst of aerosolized medicine. The available dosage forms include aerosols, dry powder, suspension, and spray, each indicated for different conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The primary end-users of these products include hospitals, outpatient clinics, home care settings, and pharmacies.

The budesonide inhaler market research report is one of a series of new reports from The Business Research Company that provides budesonide inhaler market statistics, including budesonide inhaler industry global market size, regional shares, competitors with a budesonide inhaler market share, detailed budesonide inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide inhaler industry. This budesonide inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The budesonide inhaler market size has grown strongly in recent years. It will grow from $6.37 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to heightened awareness of inhalation therapies, growing adoption of corticosteroid treatments, rising air pollution levels leading to respiratory problems, increasing demand for minimally invasive drug delivery methods, and a stronger focus on home healthcare solutions.

The budesonide inhaler market size is expected to see strong growth in the next few years. It will grow to $9.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing investments in respiratory drug development, rising demand for personalized medicine in respiratory care, greater use of telemedicine and e-prescriptions, heightened awareness of early diagnosis and treatment, and a growing preference for combination inhaler therapies. Key trends during this period include advanced formulation techniques for improved drug delivery, innovations in smart inhalers with digital tracking, the integration of AI and IoT in respiratory health management, advancements in patient-centric drug designs, and the incorporation of mobile apps for adherence monitoring.

The growing incidence of respiratory disorders is expected to drive the expansion of the budesonide inhaler market in the coming years. Respiratory disorders, which affect the lungs and airways, can make breathing difficult and often lead to symptoms such as coughing, wheezing, and shortness of breath. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. The rise in respiratory disorders is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and worsen lung function. Budesonide inhalers help manage these disorders by delivering anti-inflammatory medication directly to the lungs, providing long-term control. Their compact design ensures ease of use and portability, reducing flare-ups and improving respiratory health. For example, according to the Australian Bureau of Statistics, the prevalence of chronic obstructive pulmonary disease (COPD) in Australia increased from 2.4% in 2021 to 2.5% in 2022. As a result, the growing prevalence of respiratory disorders is fueling the growth of the budesonide inhaler market.

Leading companies in the budesonide inhaler market are increasingly focused on developing innovative products, such as generic versions, to enhance affordability and broaden access to treatment for respiratory conditions. Generic inhalers are non-branded alternatives that contain the same active ingredients, dosage, and therapeutic effects as their branded counterparts, but typically at a lower price. For example, in July 2023, Viatris Inc., in partnership with Kindeva Drug Delivery L.P., launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first FDA-approved generic version of Symbicort. This drug-device combination is designed to treat asthma and COPD by reducing airway inflammation with budesonide, while formoterol relaxes the muscles around the airways, offering a more affordable option for patients.

In January 2025, Molex, a US-based electronics company, acquired Vectura Group Ltd. for an undisclosed sum. Through this acquisition, Molex aims to establish a leading position in inhalation drug delivery by combining Phillips Medisize's manufacturing expertise with Vectura's specialization in inhalation devices and formulation development. This move will enhance Molex's ability to deliver innovative therapies for respiratory conditions. Vectura Group, based in the UK, is known for its work in developing inhalation drug delivery systems, including those used to administer budesonide.

Major players in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

North America was the largest region in the budesonide inhaler market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in budesonide inhaler report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the budesonide inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The budesonide inhaler market consists of sales of soft mist inhalers, nasal inhalers, budesonide repulse, oral inhalation capsules, and transdermal inhalation systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Budesonide Inhaler Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on budesonide inhaler market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for budesonide inhaler ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The budesonide inhaler market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Budesonide Inhaler Market Characteristics

3. Budesonide Inhaler Market Trends And Strategies

4. Budesonide Inhaler Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Budesonide Inhaler Growth Analysis And Strategic Analysis Framework

6. Budesonide Inhaler Market Segmentation

7. Budesonide Inhaler Market Regional And Country Analysis

8. Asia-Pacific Budesonide Inhaler Market

9. China Budesonide Inhaler Market

10. India Budesonide Inhaler Market

11. Japan Budesonide Inhaler Market

12. Australia Budesonide Inhaler Market

13. Indonesia Budesonide Inhaler Market

14. South Korea Budesonide Inhaler Market

15. Western Europe Budesonide Inhaler Market

16. UK Budesonide Inhaler Market

17. Germany Budesonide Inhaler Market

18. France Budesonide Inhaler Market

19. Italy Budesonide Inhaler Market

20. Spain Budesonide Inhaler Market

21. Eastern Europe Budesonide Inhaler Market

22. Russia Budesonide Inhaler Market

23. North America Budesonide Inhaler Market

24. USA Budesonide Inhaler Market

25. Canada Budesonide Inhaler Market

26. South America Budesonide Inhaler Market

27. Brazil Budesonide Inhaler Market

28. Middle East Budesonide Inhaler Market

29. Africa Budesonide Inhaler Market

30. Budesonide Inhaler Market Competitive Landscape And Company Profiles

31. Budesonide Inhaler Market Other Major And Innovative Companies

32. Global Budesonide Inhaler Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Budesonide Inhaler Market

34. Recent Developments In The Budesonide Inhaler Market

35. Budesonide Inhaler Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â